Table of contents
November 2002 - Volume 61 - suppl 2
Advances in targeted therapies IV
Preface
- Advances in targeted therapies IV (1 November, 2002)
Consensus statement
New targets
- Subversion of the innate immune response by micro-organisms (1 November, 2002)
- Is NF-κB a useful therapeutic target in rheumatoid arthritis? (1 November, 2002)
- Balancing the immune system: Th1 and Th2 (1 November, 2002)
- Mesenchymal stem cells. A potential source for skeletal repair (1 November, 2002)
- Role of RANKL and RANK in bone loss and arthritis (1 November, 2002)
- Functions of AP1 (Fos/Jun) in bone development (1 November, 2002)
- Treatments no longer in development for rheumatoid arthritis (1 November, 2002)
New look at target diseases
- Behçet’s disease: a new target for anti-tumour necrosis factor treatment (1 November, 2002)
Safety issues: tuberculosis
- Protection against tuberculosis: cytokines, T cells, and macrophages (1 November, 2002)
- Epidemiology, diagnostic possibilities, and treatment of tuberculosis (1 November, 2002)
Clinical and radiological aspects of biologics
Molecular mechanisms of cartilage and bone destruction
- Bone destruction in arthritis (1 November, 2002)
- Cartilage destruction in rheumatoid arthritis (1 November, 2002)
Regulatory aspects
- Weight and consequences of post-marketing (-approval) experience (1 November, 2002)
- The National Institute for Clinical Excellence (NICE) (1 November, 2002)
Co-stimulatory molecules
- Role of interleukin 15 and interleukin 18 in inflammatory response (1 November, 2002)